JP2015524408A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524408A5
JP2015524408A5 JP2015523158A JP2015523158A JP2015524408A5 JP 2015524408 A5 JP2015524408 A5 JP 2015524408A5 JP 2015523158 A JP2015523158 A JP 2015523158A JP 2015523158 A JP2015523158 A JP 2015523158A JP 2015524408 A5 JP2015524408 A5 JP 2015524408A5
Authority
JP
Japan
Prior art keywords
drug
mammal
pharmaceutical preparation
cells
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015523158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524408A (ja
JP6289460B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/050511 external-priority patent/WO2014014828A1/en
Publication of JP2015524408A publication Critical patent/JP2015524408A/ja
Publication of JP2015524408A5 publication Critical patent/JP2015524408A5/ja
Application granted granted Critical
Publication of JP6289460B2 publication Critical patent/JP6289460B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015523158A 2012-07-16 2013-07-15 難聴を治療するためのニコチンアミドリボシド Expired - Fee Related JP6289460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672169P 2012-07-16 2012-07-16
US61/672,169 2012-07-16
PCT/US2013/050511 WO2014014828A1 (en) 2012-07-16 2013-07-15 Nicotinamide riboside to treat hearing loss

Publications (3)

Publication Number Publication Date
JP2015524408A JP2015524408A (ja) 2015-08-24
JP2015524408A5 true JP2015524408A5 (https=) 2016-09-08
JP6289460B2 JP6289460B2 (ja) 2018-03-07

Family

ID=49949192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015523158A Expired - Fee Related JP6289460B2 (ja) 2012-07-16 2013-07-15 難聴を治療するためのニコチンアミドリボシド

Country Status (5)

Country Link
US (1) US9861651B2 (https=)
EP (1) EP2872128B1 (https=)
JP (1) JP6289460B2 (https=)
ES (1) ES2785303T3 (https=)
WO (1) WO2014014828A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3369738B1 (en) 2005-11-18 2020-05-20 Cornell Research Foundation, Inc. Method for making nicotinoyl ribosides and nicotinamide beta-riboside
AU2015270090A1 (en) 2014-06-06 2016-12-22 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
ES2882602T3 (es) 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
RS65379B1 (sr) 2016-04-14 2024-04-30 Sensorion (+)-azasetron za upotrebu u lečenju poremećaja uha
CN110248650A (zh) * 2016-10-31 2019-09-17 霍夫耳科研究所 用于增强突触发生和神经突发生的方法
EP3538099B1 (en) 2016-11-11 2026-04-22 The Queen's University of Belfast Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
JP7136795B2 (ja) 2016-11-29 2022-09-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 母体の健康および/または子の健康を向上させるためのnad前駆体の使用
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
US10961268B2 (en) 2017-04-05 2021-03-30 Cornell University β-nicotinate ester nucleotides and process for preparing same
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
BR112022000963A2 (pt) 2019-07-19 2022-04-05 Biosynth Ag Método de fabricação de sais de nicotinamida ribofuranosídeo, sais de nicotinamida ribofuranosídeo como tal e usos dos mesmos
AU2022281388A1 (en) 2021-05-27 2023-12-07 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
CN121793959A (zh) 2023-06-14 2026-04-03 可劳迈戴斯有限公司 静脉内配制品中的烟酰胺核苷及其衍生物与使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695593A5 (de) 2002-12-17 2006-06-30 Granite Trading Ltd Vorsatzlinse.
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
WO2007008548A2 (en) 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
KR20130097813A (ko) * 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물

Similar Documents

Publication Publication Date Title
JP2015524408A5 (https=)
EA201400878A1 (ru) Паразитицидные пероральные ветеринарные композиции, включающие системно действующие активные агенты, способы и применение этих композиций и способов
MX357540B (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
NZ604029A (en) Methods of treating bladder cancer
EA201190219A1 (ru) Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий
NZ611868A (en) Gastric and colonic formulations and methods for making and using them
JP2014511892A5 (https=)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ603985A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
WO2010011609A3 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
RU2010150863A (ru) Фармацевтическая композиция для лечения ушных заболеваний
UA107103C2 (uk) Нікотиновмісні м'які желатинові пастилки
WO2009052411A3 (en) Methods for treatment of thiol-containing compound deficient conditions
EA201490254A1 (ru) Комбинированное лечение гепатита с
Uchida et al. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
JP2020505432A5 (https=)
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite
Kang et al. Effect of high dose intravenous vitamin C on idiopathic sudden sensorineural hearing loss: a prospective single-blind randomized controlled trial
RU2014144951A (ru) Новое 1-замещенное производное индазола
EA201270192A1 (ru) Композиции и способы применения для пострадиационной защиты
BR112014026184A2 (pt) composições parasiticídicas compreendendo derivados de benzimidazol, métodos e seus usos
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물